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Sequestration of infected red blood cells (iRBC) within the cerebral and pulmonary microvasculature is a hallmark of human
cerebral malaria (hCM). The interaction between iRBC and the endothelium in hCM has been studied extensively and is linked
to the severity of malaria. Experimental CM (eCM) caused by Plasmodium berghei ANKA reproduces most features of hCM, al-
though the sequestration of RBC infected by P. berghei ANKA (PbA-iRBC) has not been completely delineated. The role of PbA-
iRBC sequestration in the severity of eCM is not well characterized. Using static and flow cytoadherence assays, we provide the
first direct in vitro evidence for the binding of PbA-iRBC to murine brain and lung microvascular endothelial cells (MVEC). We
found that basal PbA-iRBC cytoadherence to MVECs was significantly higher than that of normal red blood cells (NRBC) and of
RBC infected with P. berghei K173 (PbK173-iRBC), a strain that causes noncerebral malaria (NCM). MVEC prestimulation with
tumor necrosis factor (TNF) failed to promote any further significant increase in mixed-stage iRBC adherence. Interestingly,
enrichment of the blood for mature parasites significantly increased PbA-iRBC binding to the MVECs prestimulated with TNF,
while blockade of VCAM-1 reduced this adhesion. Our study provides evidence for the firm, flow-resistant binding to endothe-
lial cells of iRBC from strain ANKA-infected mice, which develop CM, and for less binding of iRBC from strain K173-infected
mice, which develop NCM. An understanding of P. berghei cytoadherence may help elucidate the importance of sequestration in
the development of CM and aid the development of antibinding therapies to help reduce the burden of this syndrome.
First described in the 19th century, sequestration, the cytoadhe-sion of infected red blood cells (iRBC) within the microvascu-
lature, is a common feature of human cerebral malaria (hCM)
(1–3). Cerebral malaria (CM) is a life-threatening encephalopa-
thy, a complication of Plasmodium falciparum infection. In the
human host, it is characterized by coma and is quantitatively as-
sociated with cerebral sequestration and total parasite biomass
(4–6). The progression of uncomplicated malaria to potentially
fatal CM remains poorly understood, though it is associated with
microcirculatory dysfunction due to the formation of cerebral le-
sions (4, 7, 8). These lesions develop when mature forms of the
parasite, trophozoites, or schizonts or immature gametocytes
bind to the endothelial cells (EC) lining small capillaries and post-
capillary venules and consequently plug the vessel lumen, placing
pressure on tight junctions of the blood-brain barrier (BBB) (9,
10). This causes downstream hypoxia within the tissue, resulting
in poor perfusion and damage to adjacent tissues (11). This, cou-
pled with the dysregulated release of cytokines and chemokines
from immune cells, contributes to the development of CM (7, 11,
12).
The vaso-occlusive sequestration of iRBC in vital organs has
potent effects on organ function. The majority of sequestered par-
asites are found in the brain, lung, spleen, liver, kidney, small
intestine, heart, and adipose tissue, as well as in the placenta in
pregnancy-associated malaria (3, 13, 14). The microaerophilic ve-
nous environment of the deep microvessels nourishes the matu-
ration of the parasites, facilitating their survival (15).
The pathogenicity of P. falciparum is partially attributed to its
ability to evade the immune system, particularly the filtration by
the spleen, through adherence to the vascular endothelium (16–
18). Numerous studies have directed their efforts at identifying
parasite virulence ligands and host endothelial cell receptors and
adhesins that mediate this cytoadhesion, with the goal of develop-
ing strategies that will reduce the incidence of CM (7, 19, 20). P.
falciparum sequestration is mediated by the interactions between
parasite ligand P. falciparum EMP1 (PfEMP1), displayed on the
surface of iRBC, and multiple receptors, such as ICAM1, CD36,
CD31, and CSA (20–23), displayed on the surface of the host cell.
Murine models of CM, particularly P. berghei ANKA, are well
established in the study of CM pathogenesis (24) and are utilized
as a preclinical model for drug testing (25). The strain ANKA
model of experimental CM (eCM) replicates most signs of hCM
(12, 26, 27), although eCM is mainly characterized by monocyte/
macrophage, T cell, and platelet sequestration (28–34) as opposed
to iRBC sequestration, which is more prominent in hCM (35, 36).
Some argue that this binding is not mediated by the interaction of
parasite ligands and endothelial receptors but rather an accumu-
lation or trapping in small blood capillaries that is more represen-
tative of stasis. For this reason, attempts have been made at creat-
ing mouse models that closely resemble hCM and reproduce the
signature iRBC microvascular sequestration (34). The field is con-
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troversial, and of the few studies on strain ANKA binding in vivo
(33, 34, 37–41), one suggests that sequestration is not linked to the
development of CM (33), and this has challenged the relevance of
the murine model to the human syndrome (42).
The interaction between iRBC and the endothelium is not pas-
sive. Parasite proteins interact with the host RBC to change its
morphology, physiology, and function (43). Parasites produce
mediators that trigger the release of cytokines from a range of host
cells, including EC. These cytokines facilitate cytoadherence by
upregulating the expression of ligands available on the surface of
host cells, and this interaction activates signaling cascades that
downregulate genes involved in the inflammatory response and
apoptosis (44). In eCM, tumor necrosis factor (TNF) has long
been known to be an important mediator in the pathogenesis of
CM (45–47). A number of factors support the adhesion of the
parasite to the endothelium, including host cells such as macro-
phages (47), lymphotoxin (48), platelets (49), and plasma micro-
particles (50). iRBC can directly stimulate the endothelium in the
absence of proinflammatory cytokines, inducing the expression of
adhesion molecules and chemokines and mimicking the effects
caused by cytokines such as TNF (51–55).
Sequestration of iRBC in the microvasculature has been impli-
cated in the severity of P. falciparum infection, as reviewed in
reference 56, and in eCM, with P. berghei ANKA sequestering in
analogous fashion, albeit to a less pronounced degree (15, 33, 34,
57). Postmortem studies show a strong association between the
number of tightly packed RBC in vessels and hCM (2, 36) and also
in eCM (58, 59). In patients dying from P. falciparum infection,
sequestered iRBC are higher in CM than in noncerebral malaria
(NCM), and brain and lung are sites of this vascular pathology (2,
3, 36). Murine models of CM have provided histopathological
evidence for iRBC sequestration on cerebral microvascular endo-
thelium (34, 37, 40, 59, 60) and in the lung and adipose tissue (15,
33), as well as leukocyte sequestration in retinal vessels (61), al-
though no direct evidence exists to delineate this phenomenon as
being either iRBC accumulation or sequestration. CD36-medi-
ated sequestration has been described in both hCM and eCM,
although the corresponding ligand proteins are not the same (15).
PfEMP1 mediates CD36 binding in hCM (62) and the rodent
equivalent has not yet been identified, although deletions studies
have ruled out SMAC, bir, pb-fam-1, and pb-fam-3 multigene
families as potential parasite proteins mediating adhesion (15).
No data exist on the ability of RBC infected by P. berghei ANKA
(PbA-iRBC) or P. berghei K173 (PbK173-iRBC) to firmly adhere
to the microvascular endothelium, a mechanism that may under-
lie CM pathogenesis. A more complete understanding of the
mechanisms involved in iRBC sequestration is required, so that
strategies to prevent adhesion can be developed and implemented
to reduce disease burden. Here, we describe an adapted assay that
isolates the sequestration phenomenon in eCM. In this study, we
have used an in vitro coculture assay in which freshly isolated RBC
are incubated with murine MVEC from the brain and lung to
quantify binding. We provide the first direct in vitro evidence for
binding of PbA-iRBC to murine brain (B3) and lung (L2) MVEC.
We investigated under static and/or flow conditions the cytoad-
herence of PbA-iRBC parasites to TNF-activated murine brain
and lung MVEC and compared it to PbK173-iRBC, with these
being used to model NCM. Mice infected with large P. berghei
K173 inocula develop high parasitemia levels and anemia and die
without cerebral signs at least 14 days postinfection (27). Further-
more, we assessed the involvement of the endothelial molecules
ICAM-1 and VCAM-1, known to mediate P. falciparum cytoad-
herence and present on our MVEC lines, in the observed binding.
MATERIALS AND METHODS
Research procedures were approved by the Animal Ethics Committee of
the University of Sydney (K20/7-2006/3/4434 and K00/10-2010/3/5317).
Microvascular endothelial cells. Primary mouse brain MVEC (B3)
were isolated as described previously (63). Primary mouse lung MVEC
(L2) were derived from primary cultures of peripheral lung parenchyma
of CBA/Ca mice. These cells have been immortalized by transfection of a
plasmid construct containing Bcl-XL protein. Cells were seeded in culture
flasks and grown to confluence in RPMI 1640 medium supplemented
with 10% fetal bovine serum at 37°C in 5% CO2.
Surface phenotyping of B3 and L2 cells. Monolayers of B3 and L2 cells
were cultured until confluence and then either left unstimulated or incu-
bated with recombinant murine TNF (10 ng/ml; Peprotech) for 4 h or
overnight. Cells were then washed in phosphate-buffered saline (PBS) and
exposed to a short trypsin-EDTA treatment to harvest a cell suspension.
To identify resting and activated cellular markers, the cells were directly
labeled using anti-mouse monoclonal antibodies directed against
PECAM-1, ICAM-1, integrin beta-3, endoglin, VCAM-1, and E-selectin
(CD31, CD54, CD61, CD105, CD106, and CD62E, respectively; eBiosci-
ence) and their respective isotype-matched immunoglobulins. Cells were
then resuspended in PBS prior to flow-cytometric analysis (Beckman
Coulter FC500). E-selectin was measured after a 4-h TNF treatment, while
the remaining molecules were measured after an overnight treatment.
Preparation of red blood cells. Infection was induced in 8-week-old
CBA female mice by intraperitoneal injection of 1  106 P. berghei ANKA-
or 2  106 P. berghei K173-parasitized RBCs as described previously (26,
27). Blood was collected in citrated tubes via retro-orbital sampling from
infected mice 6 days postinfection, while noninfected mice were used as
controls. Parasitemia was determined by Diff-Quick-stained thin tail vein
blood smears.
Red blood cells were separated from whole blood by centrifugation at
500  g for 5 min and were washed at low speed in PBS three times.
Mixed-stage RBC were used at 6 to 7% parasitemia. Mature-stage iRBC
were selected and concentrated using automatic magnetically activated
cell sorting (MACS) as previously described (64). Enriched RBC were
used at 40% parasitemia with 70% of the parasites at the mature stage. Red
blood cells were labeled with green fluorescent Calcein-acetoxymethyl
(Calcein-AM) (Molecular Probes) and resuspended in medium. Briefly,
1  107 RBC were washed in Dulbecco’s modified Eagle medium without
phenol red (DMEM; Gibco) and loaded with 1 g/ml Calcein-AM for 30
min at 37°C. Subsequently, cells were washed, resuspended in 10 ml
DMEM, and allowed to rest for 30 min; this procedure was repeated twice.
RBC were checked for optimal loading of dye on an Olympus IX71 in-
verted microscope.
Static cytoadherence assays. B3 and L2 cells were cultured to conflu-
ence on 24-well plates. Cells were either left unstimulated or were acti-
vated overnight with 50 ng/ml murine TNF. The MVEC were then washed
in medium and incubated with RBC (RBC/MVEC ratio, 20:1) for 90 min
at 37°C. Nonadherent RBCs were then removed by gentle washing in
medium, followed by more thorough washing with PBS and plate inver-
sion. Remaining cells were fixed by incubation with 1% (wt/vol) parafor-
maldehyde at 4°C overnight. Bound RBCs were counted on at least 15
fields from 3 separate experiments imaged on an Olympus IX71 inverted
microscope (400 magnification).
Flow cytoadherence assays. Cell adherence assays were performed
using parallel-plate flow chambers (Glycotech). Confluent monolayers of
B3 and L2 cells, seeded in 35-mm petri dishes, were stimulated with TNF
by following the same regimen as that for the static conditions. RBC were
resuspended at 1% hematocrit and perfused over endothelial monolayers
for 15 min at a shear stress of 0.5 dynes/cm2. Plates were washed and fixed
prior to imaging (Olympus IX71 inverted microscope at 400 magnifi-
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cation). The total number of bound RBC was determined through analy-
sis of 15 random fields from 3 separate experiments.
Cytoadhesion inhibition assays. To identify possible receptors in-
volved in the adhesion, we tested the inhibitory activity of ICAM-1 and
VCAM-1 antibodies. Mature PbA-iRBC were incubated with MVECs, as
described above for static cytoadherence assays, in the presence of 10
g/ml purified anti-mouse ICAM-1 and anti-mouse VCAM-1 (LEAF)
(BioLegend). These concentrations have been shown previously to effec-
tively block ICAM-1 (65) and VCAM-1 cell-to-cell adhesion and function
(66, 67). Inhibition assays were also carried out in the presence of corre-
sponding isotype-matched controls, purified rat IgG2a, and IgG2b,
(LEAF) (BioLegend).
Statistical analyses. The results of the cytoadhesion and inhibition
assays are expressed as means  standard errors of the means (SEM). All
statistical analyses were performed using GraphPad Prism 5.0 (GraphPad
Software Inc.). To compare several groups in the static assays, we used
nonparametric analysis of variance (ANOVA; Kruskall-Wallis) with a
Dunn’s posttest. The Mann-Whitney test was used to evaluate the statis-
tical significance in the flow assays, and P values of 0.05 were deemed
significant.
RESULTS
Adhesion of P. berghei-iRBC to murine brain and lung micro-
vascular endothelial cells under static conditions. Static cytoad-
herence assays were performed using fresh blood samples ob-
tained directly from uninfected mice and mice at 6 days
postinfection. We first studied the binding of mixed-stage iRBC
on monolayers of B3 and L2 cells. Ninety minutes after incubation
with RBC and removal of nonadherent cells, we found that PbA-
iRBC bound significantly more than NRBC and PbK173-iRBC to
both B3 and L2 MVECs, and that prestimulation with TNF did not
affect the level of cytoadherence of any of the RBC tested (Fig. 1).
Interestingly, more PbA-iRBC adhesion was observed on brain
MVEC than on lung MVEC.
Both B3 and L2 cells readily adhere to plastic culture flasks and
exhibit contact inhibition. Figure 1 demonstrates the clear bind-
ing of mixed-stage fluorescent-labeled iRBC from strain ANKA-
infected mice to B3 monolayers. Similar binding was seen on L2
monolayers (data not shown).
Firm, flow-resistant binding of PbA-iRBC to murine brain
and lung microvascular endothelial cells. Following the demon-
stration that PbA-iRBC cytoadherence to MVEC under static con-
ditions was greater than that of NRBC and PbK173-iRBC, we eval-
uated the strength of the cytoadherence of PbA-iRBC under more
biologically relevant conditions. Flow cytoadherence assays were
conducted on B3 and L2 monolayers at a shear stress of 0.5 dynes/
cm2, consistent with what is measured in the microvasculature
and used in in vitro assays (68). Under flow conditions, basal PbA-
iRBC cytoadherence to B3 and L2 MVECs was significantly higher
than that of NRBC (Fig. 2). As seen in the static assays, MVEC
prestimulation with TNF failed to induce any further increase in
RBC adherence, and fewer RBC bound to lung MVEC monolayers
than brain MVEC monolayers.
Phenotyping of B3 and L2 cells under resting and inflamma-
tory conditions. The surface phenotype of both cell lines in rest-
ing and inflammatory conditions was assessed by flow cytometry
(Fig. 3). In resting conditions, cells expressed CD54 (ICAM-1)
and CD106 (VCAM-1). Following overnight TNF stimulation,
both ICAM-1 and VCAM-1 were markedly upregulated on B3
(mean fluorescent intensity [MFI], 3.73 versus 8.19; 2.88 versus
11.6) and L2 cells (MFI, 4.54 versus 10.5; 5.55 versus 20).
Enrichment for mature parasites increases the level of PbA-
iRBC binding on MVECs prestimulated with TNF, and blocking
VCAM-1 reduces this binding. To investigate the effect of TNF
on the binding of iRBC harboring mature stages of the parasite,
blood was enriched for mature forms and incubated on B3 mono-
layers in resting and activated conditions. Prestimulation with
TNF significantly increased the number of mature PbA-iRBC
bound compared to that of resting monolayers (Fig. 4). We found
no difference between the binding of mature PbA-iRBC and
NRBC on resting monolayers (Fig. 1, 3, and 4).
The upregulation of adhesion molecules ICAM-1 and
VCAM-1 on the surface of B3 and L2 cells represented potential
FIG 1 (A) Adhesion of Plasmodium berghei ANKA- and K173-infected red
blood cells to murine brain and lung microvascular endothelial cells. Static
assays were performed as described in Materials and Methods; notably, mixed-
stage iRBC were incubated for 90 min on resting or activated (TNF, 50 ng/ml)
endothelial cells. More PbA-iRBC than NRBC and PbK173-iRBC bound to
both B3 and L2 MVECs. Data shown are the mean numbers  SEM of RBC per
field of view from at least 15 fields from 3 separate experiments (*, P  0.05).
(B) Adhesion of Plasmodium berghei ANKA-infected red blood cells on TNF-
stimulated murine brain microvascular endothelial monolayers. Representa-
tive bright-field image with fluorescent Calcein-labeled RBC on TNF-acti-
vated (50 ng/ml) brain MVEC (400 magnification; Olympus IX71 inverted
microscope). In the magnified inset, arrows indicate bound RBC.
FIG 2 Firm, flow-resistant binding of PbA-iRBC to murine brain and lung
microvascular endothelial cells. RBC were resuspended at 1% hematocrit and
perfused over endothelial monolayers for 15 min at a flow rate of 0.227 ml/min
in a flow chamber. More PbA-iRBC adhered than did NRBC, despite a shear
stress of 0.05 Pa being maintained in the flow chamber. Data shown are the
mean numbers  SEM of RBC per field of view from at least 15 fields from 3
separate experiments (*, P  0.05).
El-Assaad et al.
3986 iai.asm.org Infection and Immunity
 on S
eptem


























receptors by which the RBC were binding under experimental
inflammatory conditions (Fig. 4). To address this possible inter-
action, B3 monolayers were incubated with purified anti-mouse
ICAM-1 or anti-mouse VCAM-1 (LEAF) and their respective iso-
type-matched controls. These monoclonal antibodies selectively
block ICAM-1 binding to LFA-1 and Mac-1 receptors, as well as
VCAM-1 binding to VLA-4 (41 integrin) and LPAM-1 (47
integrin) receptors. A 65% reduction in the number of PbA-iRBC
was observed when blocking VCAM-1, whereas no effect was seen
when blocking ICAM-1 or when the isotype-matched controls
were used. The addition of the blocking antibodies had no effect
on the number of binding NRBC compared to that of isotype
controls.
DISCUSSION
This study describes our findings on the cytoadherence of P. ber-
ghei-iRBC to murine brain (B3 cells) and lung (L2 cells) MVEC.
First, our data provide the first direct in vitro evidence, to our
knowledge, that PbA-iRBC are capable of cytoadhering to murine
brain and lung MVEC. Second, the proportion of binding is
higher for RBC infected with strain ANKA, the strain causing
eCM, than those infected with strain K173, the strain causing
NCM, and this binding is independent of endothelial cell pre-
stimulation by TNF. Third, this binding is firm, shear stress resis-
tant, and significantly higher on brain than on lung MVEC. Fi-
nally, enriched mature PbA-iRBC bind to TNF-activated MVEC
to a greater extent than to resting MVEC, and this binding is
reduced when VCAM-1 is blocked on the endothelial surface.
In our study, the binding of fluorescent iRBC from strain
ANKA- and strain K173-infected mice to brain MVEC was clearly
visible, with PbA-iRBC binding more than PbK173-iRBC. Brain
sections from mice infected with the nonsequestering line P. ber-
ghei K173 display little to no sequestered parasites (69), similar to
what is observed in severe human malaria without coma (3, 4, 6,
14, 36, 70, 71). On lung MVEC we also observed binding of PbA-
FIG 3 Phenotyping of B3 and L2 cells under resting and inflammatory con-
ditions. Endothelial cells were activated with TNF (10 ng/ml) or allowed to rest
for 24 h prior to direct immunolabeling and subsequent flow cytometry anal-
ysis. The cell surface expression levels of ICAM-1 and VCAM-1 on resting (red
line) and TNF-activated (blue line) B3 and L2 cell lines are demonstrated.
Histograms are representative of three experiments and show the number of
cells positively labeled with these antibodies and their corresponding isotype
controls (shaded gray).
FIG 4 Enrichment for mature parasites increases the number of RBC bound to TNF-stimulated endothelium, and this binding is VCAM-1 dependent.
Prestimulation with TNF significantly increased the number of mature PbA-iRBC bound compared to that for resting monolayers. Binding of mature PbA-iRBC
was reduced in the presence of monoclonal antibody raised against VCAM-1 but not ICAM-1. Data shown are the mean numbers  SEM of RBC per field of view
(magnification, 400) from at least 15 fields from 3 separate experiments (*, P  0.05). ctrl, control.
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iRBC, although overall it was lower than that observed on brain
MVEC. We found no difference in binding of mixed-stage PbA-
iRBC in resting or TNF-activated conditions (Fig. 1). The cytoad-
herence-linked virulence of the parasite, as displayed by strain
ANKA, may support its ability to influence the development of
CM in the host. It would be advantageous for early-stage parasites
to directly activate the host endothelium to support adhesion in
order to enable survival and transmission in vivo (51). In our
system, RBC were sampled directly from the peripheral blood of
mice on the day of experimentation; thus, there is no influence of
long-term culture, i.e., loss of the cytoadherent phenotype (72).
Based on these observations, a series of flow assays was per-
formed to confirm the binding under physiological conditions,
similar to what is observed inside a microvessel. PbA-iRBC bind-
ing withstood flow conditions, confirming that the majority of the
interactions did not resemble stasis or weak binding but true cy-
toadherence, and the interaction was firm and flow resistant (Fig.
2). However, we did observe lower levels of binding under flow
conditions across the brain and lung endothelium, confirming
that shear stress rates significantly affect cytoadherence, and that
some of the binding seen under static conditions is indeed due to
stasis or weak binding.
Our data demonstrate that increased binding of mature para-
sites compared to mixed-stage parasites occurs following TNF
stimulation. In vivo, strain ANKA schizonts disappear from the
peripheral circulation and have a distinct sequestration phenotype
(33, 73, 74). In our system, we hypothesized that mature parasites
and schizonts would bind more than mixed-stage parasites, as
seen with P. falciparum (3, 75). Surprisingly, under resting condi-
tions these mature parasites bound no differently than NRBC.
However, under inflammatory conditions (TNF-stimulated
monolayers), we observed a significant increase in the number of
bound mature-stage PbA-iRBC (Fig. 4).
In order to determine the possible binding mechanism present
in our assay, we studied inducible receptors present on the surface
of the MVEC. From the candidate receptors present on B3 and L2
cells (Fig. 3), we focused on those upregulated following TNF
activation, namely, ICAM-1 and VCAM-1, mimicking the inflam-
matory conditions seen in CM. Previous studies have shown that
ICAM-1 and VCAM-1 expression is upregulated by TNF on en-
dothelial cells, and these molecules are receptors for P. falciparum
(76). ICAM-1 becomes upregulated on the brain and lung endo-
thelium during eCM (77–79) and is known to mediate iRBC bind-
ing to the vascular endothelium (80). Moreover, there is evidence
for the colocalization of sequestration and ICAM-1 expression in
the brain in CM (81). Surprisingly, in our study, inhibition of
ICAM-1 had no significant effect on binding of mature-stage
PbA-iRBC to brain (Fig. 4) or lung MVEC (data not shown).
Further experiments using other clones of ICAM-1 are required to
confirm whether this lack of effect is due to the blocking antibody
or the noninvolvement of ICAM-1.
There is evidence for a role for VCAM-1 in P. falciparum se-
questration (76, 82, 83). In clinical malaria, P. falciparum-infected
RBC roll and adhere to VCAM-1, although the epitope involved in
the interaction is not yet known (84, 85). Our study demonstrates
that VCAM-1 may be important in maintaining the adherence of
mature PbA-iRBC to the cerebral endothelium (Fig. 4), since
binding was inhibited in the presence of an anti-VCAM-1 mono-
clonal antibody (Fig. 4). The binding of PbA-iRBC in cultures may
be a result of the interaction between VCAM-1 and parasite li-
gands or VLA-4-like antigen present on the surface of RBC, al-
though further studies are required to determine this.
In other studies, CD36 has been identified as the host cell re-
ceptor for PbA-iRBC adherence. This is also one of the major
receptors of P. falciparum iRBC and could account for the differ-
ential binding observed on brain and lung MVEC (33). Ortho-
logues of PfEMP1 are absent from P. berghei and, as yet, strain
ANKA ligands for CD36 have not been identified (62). Interest-
ingly, mice express little or no CD36 in the brain (86) and CD36-
mediated sequestration of P. berghei is not necessary for eCM,
since cerebral complications still develop in the absence of this
molecule (33). Although the lung is a site of pathology in CM,
pulmonary sequestration of iRBC is not necessary for the devel-
opment of acute lung injury or CM (87). However, peripheral
parasite burden induces acute lung injury in eCM (79). In mice
infected with the nonencephalitic strain, K173, lung pathology
develops in the absence of CM (88) and at low inoculum size can
induce CM without evidence for sequestration (89, 90). Alterna-
tive adhesion pathways that may be responsible for the binding are
still unknown.
Our work demonstrates that mixed-stage PbA-iRBC, contain-
ing the parasite strain that causes CM, can bind firmly to the
cerebral endothelium in the absence of TNF. However, mature
parasites may require TNF to bind, and VCAM-1 could be medi-
ating this binding (Fig. 4). Our in vitro model isolates three major
components of the cerebral lesion: the endothelial cell, the RBC,
and the parasite. However, there are other effectors in the CM
lesion; thus, our data require careful interpretation. Nevertheless,
target organ-specific cell lines, such as B3 and L2, expressing cy-
toadherence receptors for PbA-iRBC may provide a solid in vitro
system that supplements the eCM model to study molecular
mechanisms of strain ANKA binding. Future work may involve
the addition of platelets, MP, and leukocytes to the system in order
to model closely what is seen in vivo (10, 49). Existing eCM models
enable access to a large library of genetically modified mice from
which MVEC from various organs could be purified. Further ex-
periments are required to identify which receptors are recognized
by P. berghei parasites and discern the specific parasite stages of the
intraerythrocytic cycle that bind. Ultimately, this could reveal how
parasites use cytoadherence to evade the immune system inside
the host, how they contribute to the severity of disease, and how
therapies work at interfering with this binding to lessen the global
burden of CM (91, 92).
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